Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.
Ressources
Commentaire | 2023
l'approvisionnement plus sécuritaire, les stimulants, à propos des prescripteurs, la politique / le cadre de réglementation, les guides de pratique clinique
The purpose of this guidance is to provide policy recommendations for territorial, provincial and federal takehome naloxone (THN) programs, using evidence from scientific and grey literature and co
Guidelines | 2023
Policy/Regulatory, Harm reduction, Clinical guidance, Overdose
Cours de formation | 2023
la douleur chronique, à propos des prescripteurs, les guides de pratique clinique
Training | 2023
Chronic pain, About prescribers, Clinical guidance
We discuss major domains of xylazine’s harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine’s public health and policy context.
Lit review | 2023
About prescribers, Illegal drugs, Harm reduction, Clinical guidance
Commentary | 2023
Overdose, Illegal drugs, Clinical guidance
Guide | 2023
à propos des pharmaciens, à propos des prescripteurs, les guides de pratique clinique, la politique / le cadre de réglementation, l'hésitation des prescripteurs, l'approvisionnement plus sécuritaire
Responding to letters about this article: https://www.cmaj.ca/content/195/27/E934
Letter | 2023
Clinical guidance, Harm reduction, About prescribers, Safer supply, Stimulants
Our objective was to provide preventive care recommendations that promote health equity by prioritizing effective interventions for people experiencing disadvantages.
Guidelines | 2023
Equity, Clinical guidance
Are higher doses of buprenorphine treatment for opioid use disorder associated with improved retention in treatment when use of fentanyl (vs heroin) is more prevalent?
Original research | 2023
Substitution/OAT, Transitions in care/treatment, Clinical guidance
Inpatient guidelines for methadone titration do not exist, whereas outpatient guidelines lack flexibility and do not consider individual opioid tolerance.
Original research | 2023
Hospitals, Substitution/OAT, Transitions in care/treatment, Clinical guidance, About prescribers, Outcomes
Commentary | 2023
Safer supply, Stimulants, About prescribers, Policy/Regulatory, Clinical guidance
Case study | 2022
Withdrawal, Clinical guidance, Hospitals
Case study | 2023
Withdrawal, Hallucinogens/psychedelics, Clinical guidance
This clinical considerations document is based on a narrative literature review and expert consensus and will specifically address considerations for changes to the clinical practice of
Lit review | 2023
Substitution/OAT, Withdrawal, Clinical guidance, About prescribers
The present meta-analysis was conducted to evaluate the efficacy and safety of tramadol in the treatment of opioid withdrawal.
Original research | 2023
Withdrawal, Clinical guidance
Measure general substance use severity, to examine for differential item functioning (DIF) across substances (i.e., sedatives, opioids, amphetamines, cocaine, and cannabis).
Original research | 2023
Clinical guidance
Case study | 2023
Wrap-around services, Illegal drugs, Clinical guidance
Opioid analgesics are commonly used for acute low back pain and neck pain, but supporting efficacy data are scarce.
Original research | 2023
Chronic pain, Clinical guidance
Report | 2023
Overdose, Clinical guidance, Workplace
